Fundz
Following Celltrion?

Get the free weekly contract digest

The latest new contracts, like Celltrion’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Celltrion Acquires iQone Healthcare Switzerland to Strengthen Its European Expansion

Nov 14, 2024•over 1 year ago

Contract Type

partnership

IncheonManufacturingBiotechnologyTherapeuticsPharmaceuticalBiopharma

Description

Celltrion has announced the acquisition of iQone Healthcare Switzerland, a specialty pharmaceutical company, to further build its expertise and foothold in Europe. The acquisition represents a strategic shift in Celltrion’s growth strategy, leveraging acquisitions to accelerate its European expansion and access in-licensing opportunities.

Company Information

Company

Celltrion

Location

Incheon, Seoul, South Korea

About

Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for several products, enhancing its portfolio in the biopharmaceutical industry.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Celltrion's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.